Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 28.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-1.5%)
  • Dividend yield for the last twelve months 2.3%
  • Free cash flow yield -2.6% (LTM)
  • Share price is 87.6% higher than minimum and -0.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (-35.6x vs
    )
  • For the last 3 months insiders sold company shares on $51.6 mln (-0.016% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (0.0%)131.78
year average price 111.89  


year start price 105.92 2023-03-30

min close price 100.18 2023-11-28

max close price 131.75 2024-03-27

current price 131.75 2024-03-28
Common stocks: 2 528 810 012

Dividend Yield:  2.3%
FCF Yield LTM: -2.6%
EV / LTM EBITDA: -35.6x
Last revenue growth (y/y):  5.8%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  8.3%
Historical growth of EBITDA:  -11.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 333 247
Net Debt ($m): 26 140
EV (Enterprise Value): 359 387
EBITDA LTM ($m): -10 103
EV / LTM EBITDA: -35.6x
Price to Book: 8.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-03-27CNBC Television

Three-Stock Lunch: Tesla, Merck, and RH

2024-03-27Proactive Investors

Merck shares move higher as lung disorder drug secures ‘squeaky clean' label from FDA

2024-03-27Schaeffers Research

Merck Stock Nabs Record High After FDA Approval

2024-03-27Zacks Investment Research

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

2024-03-27Zacks Investment Research

Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair

2024-03-26Market Watch

Merck shares rise on FDA approval for Winrevair

2024-03-26CNBC

FDA approves Merck's drug for rare, deadly lung condition

2024-03-26Reuters

US FDA approves Merck's blood pressure therapy

2024-03-26WSJ

Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives

2024-03-22Zacks Investment Research

Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data